Comparing Carbon Ion Therapy, Surgery, and Proton Therapy for Management of Pelvic Sarcomas Involving the Bone
Key facts
- Where
- Jacksonville, Rochester, and Scottsdale, United StatesSee the 3 sites
Where in United States
- Mayo Clinic in FloridaJacksonville, United StatesTaking people
- Mayo Clinic in RochesterRochester, United StatesTaking people
- Mayo Clinic in ArizonaScottsdale, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Mayo Clinic
- Trial code
- NCT05033288
- Record updated
- 13 March 2026
- Original description
This study compares carbon ion therapy, surgery, and proton therapy to determine if one has better disease control and fewer side effects. There are three types of radiation treatment used for pelvic bone sarcomas: surgery with or without photon/proton therapy, proton therapy alone, and carbon ion therapy alone. The purpose of this study is to compare quality of life among patients treated for pelvic bone sarcomas across the world, and to determine if carbon ion therapy improves quality of life compared to surgery and disease control compared with proton therapy.Read full original descriptionShow less
Prospective Comparative Effectiveness Trial of Carbon Ion Therapy, Surgery, and Proton Therapy for the Management of Pelvic Sarcomas (Soft Tissue/Bone) Involving the Bone
This study compares carbon ion therapy, surgery, and proton therapy to determine if one has better disease control and fewer side effects. There are three types of radiation treatment used for pelvic bone sarcomas: surgery with or without photon/proton therapy, proton therapy alone, and carbon ion therapy alone. The purpose of this study is to compare quality of life among patients treated for pelvic bone sarcomas across the world, and to determine if carbon ion therapy improves quality of life compared to surgery and disease control compared with proton therapy.
Inclusion: Males and females >= 15 years of age; Newly diagnosed, histologic confirmation of pelvic chordoma, chondrosarcoma, osteosarcoma, Ewing sarcoma with bone involvement, rhabdomyosarcoma (RMS) with bone involvement or non-RMS soft tissue sarcoma with bone involvement; No evidence of distant sarcoma metastases as determined by clinical examination and any form of imaging; Eastern Cooperative Oncology Group (ECOG) performance status (PS) =< 2; Patients capable of childbearing must agree to use adequate contraception; Ability to complete questionnaire(s) by themselves or with assistance; Ability to provide written informed consent; Chemotherapy per institutional guidelines is allowed.
Exclusion: Patients receiving palliative treatment; Previous radiation therapy to the site of the sarcoma or area surrounding it such that it would be partially or completely encompassed by the radiation volume needed to treat the current sarcoma. In other words, treatment on this study would require re-irradiation of tissues; Recurrent disease; Males and females < 15 years of age; Patients with distant sarcoma metastases; Benign pelvic bone histologies; Any of the following:; Pregnant women; Nursing women; Men or women of childbearing potential who are unwilling to employ adequate contraception.